Relevant bibliographies by topics / Lysergic acid diethylamide (LSD)

Contents

  1. Journal articles
  2. Dissertations / Theses
  3. Books
  4. Book chapters

Academic literature on the topic 'Lysergic acid diethylamide (LSD)'

Author: Grafiati
Published: 4 June 2021
Last updated: 7 February 2022

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Lysergic acid diethylamide (LSD).'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Lysergic acid diethylamide (LSD)"

1

Ritter, Detlef, Cherise M. Cortese, Linda C. Edwards, Judith L. Barr, Hyung D. Chung, and Christopher Long. "Interference with testing for lysergic acid diethylamide." Clinical Chemistry 43, no. 4 (1997): 635–37. http://dx.doi.org/10.1093/clinchem/43.4.635.

Full text
Abstract:
Abstract We found a high rate (4.2%) of positive results for lysergic acid diethylamide (LSD) by Emit in 1898 urine samples that were submitted primarily from psychiatric patients for drugs-of-abuse (DOA) testing. Specimens that tested positive for LSD by Emit subsequently tested negative for LSD with two RIAs. Furthermore, LSD was not detected in randomly selected Emit-positive urine samples by gas chromatography–mass spectrometry. Normal urine samples tested positive for LSD by Emit when they were supplemented with therapeutic medications that were prescribed for patients with positive urine LSD results by Emit. These therapeutic drugs interfered specifically with the Emit assay for LSD, since other Emit DOA tests were not affected by these medications at the tested concentrations.
APA, Harvard, Vancouver, ISO, and other styles
2

Suryaningsih, Chatarina, and Soleha Hendarsyah. "Pengalaman Anak Jalanan Usia Remaja Dalam Perilaku Inhalasi Lysergic Acid Diethylamide." Jurnal Ilmu Keperawatan Anak 2, no. 2 (2019): 40. http://dx.doi.org/10.32584/jika.v0i0.345.

Full text
Abstract:
Seorang anak bisa menjadi anak jalanan tentu mempunyai hal yang melatarbelakangi dalam kehidupannya. Sehingga anak jalanan sangat rentan untuk terjerumus kedalam perilaku menyimpang salah satunya adalah perilaku inhalasi zat adiktif seperti Lysergic Acid Diethylamide (LSD). Tujuan penelitian ini untuk mengeksplorasi dan menggambarkan pengalaman anak jalanan usia remaja dalam perilaku inhalasi LSD. Jenis penelitian ini adalah penelitian kualitatif dengan pendekatan fenomenologi deskriptif untuk menggambarkan pengalaman anak jalanan usia remaja dalam perilaku inhalasi LSD. Empat partisipan terpilih dengan menggunakan metode purvosive sampling dan memenuhi kriteria anak jalanan yang berpengalaman melakukan perilaku inhalasi LSD di daerah Contong dan Cimindi kota Cimahi. Pengumpulan data dilakukan melalui wawancara mendalam dan dilengkapi dengan catatan lapangan, sesuai dengan tempat yang telah disepakati oleh peneliti dan partisipan. Wawancara mendalam direkam kemudian dibuat transkrip verbatim dan dianalisis dengan menggunakan metode Colaizzi. Hasil penelitian menggambarkan pengalaman anak jalanan usia remaja dalam perilaku inhalasi Lysergic Acid Diethylamide dengan berbagai pengalamannya. Hasil penelitian ini menghasilkan 4 tema penelitian yaitu : 1. Faktor penyebab menjadi anak jalanan, 2. Faktor penyebab anak melakukan perilaku mengelem, 3. Dampak yang ditimbulkan ketika anak jalanan mengelem, 4. Stigma terhadap perilaku mengelem anak jalanan. Kata kunci: pengalaman anak jalanan, remaja, perilaku inhalasi lysergic acid diethylamideThe Experience of Street Children in Their Teens in Lysergic Acid Diethylamide Inhalation BehaviorAbstractA child can be a street child certainly has a background in his life. So that street children are very susceptible to fall into deviant behavior, one of which is the inhalation behavior of addictive substances such as Lysergic Acid Diethylamide (LSD). The purpose of this study is to explore and describe the experiences of street children in their teens in LSD inhalation behavior. This type of research is a qualitative research with a descriptive phenomenological approach to describe the experience of street children in their teens in LSD inhalation behavior. Four participants were selected using a purposive sampling method and fulfilled the criteria of street children who experienced inhaled LSD behavior in the Contong and Cimindi areas of Cimahi city. Data collection was carried out through in-depth interviews and supplemented with field notes, according to the place agreed upon by the researchers and participants. In-depth interviews were recorded and then verbatim transcripts were made and analyzed using the Colaizzi method. The results of this study describe the experiences of teenage street children in inhalation behavior of Lysergic Acid Diethylamide with various experiences. The results of this study resulted in 4 research themes, namely: 1. Factors that cause street children to be, 2. Factors that cause children to glue behavior, 3. Impacts caused when street children glue, 4. Stigma on the behavior of gluing street children. Keywords: experience of street children, adolescents, lysergic acid diethylamide inhalation behavior
APA, Harvard, Vancouver, ISO, and other styles
3

Libânio Osório Marta, Rui Filipe. "Metabolism of lysergic acid diethylamide (LSD): an update." Drug Metabolism Reviews 51, no. 3 (2019): 378–87. http://dx.doi.org/10.1080/03602532.2019.1638931.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Perera, K. M. H., A. Ferraro, and M. R. M. Pinto. "Catatonia LSD Induced?" Australian & New Zealand Journal of Psychiatry 29, no. 2 (1995): 324–27. http://dx.doi.org/10.1080/00048679509075930.

Full text
Abstract:
The case of a patient who developed catatonia one week following Lysergic Acid Diethylamide (LSD) ingestion is presented. The psychosis developed two days after the intake. The catatonic syndrome resolved dramatically following one treatment of electroconvulsive therapy (ECT). This is perhaps the first case report of catatonia following the use of LSD. The need for a diagnostic category of organic catatonia is highlighted.
APA, Harvard, Vancouver, ISO, and other styles
5

Tsochatzis, Emmanouil, Joao Alberto Lopes, Fabiano Reniero, Margaret Holland, Jenny Åberg, and Claude Guillou. "Identification of 1-Butyl-Lysergic Acid Diethylamide (1B-LSD) in Seized Blotter Paper Using an Integrated Workflow of Analytical Techniques and Chemo-Informatics." Molecules 25, no. 3 (2020): 712. http://dx.doi.org/10.3390/molecules25030712.

Full text
Abstract:
The rapid dispersion of new psychoactive substances (NPS) presents challenges to customs services and analytical laboratories, which are involved in their detection and characterization. When the seized material is limited in quantity or of a complex nature, or when the target substance is present in very small amounts, the need to use advanced analytical techniques, efficient workflows and chemo-informatics tools is essential for the complete identification and elucidation of these substances. The current work describes the application of such a workflow in the analysis of a single blotter paper, seized by Swedish customs, that led to the identification of a lysergic acid diethylamide (LSD) derivative, 1-butyl-lysergic acid diethylamide (1B-LSD). Such blotter paper generally contains an amount in the range of 30–100 ug. This substance, which is closely related to 1-propionyl-lysergic acid diethylamide (1P-LSD), seems to have only recently reached the drug street market. Its identification was made possible by comprehensively combining gas chromatography with mass spectrometry detection (GC–MS), liquid chromatography coupled with high-resolution tandem MS (LC–HR-MS/MS), Orbitrap-MS and both 1D and 2D nuclear-magnetic-resonance (NMR) spectroscopy. All the obtained data have been managed, assessed, processed and evaluated using a chemo-informatics platform to produce the effective chemical and structural identification of 1B-LSD in the seized material.
APA, Harvard, Vancouver, ISO, and other styles
6

Carhart-Harris, R. L., M. Kaelen, M. Bolstridge, et al. "The paradoxical psychological effects of lysergic acid diethylamide (LSD)." Psychological Medicine 46, no. 7 (2016): 1379–90. http://dx.doi.org/10.1017/s0033291715002901.

Full text
Abstract:
BackgroundLysergic acid diethylamide (LSD) is a potent serotonergic hallucinogen or psychedelic that modulates consciousness in a marked and novel way. This study sought to examine the acute and mid-term psychological effects of LSD in a controlled study.MethodA total of 20 healthy volunteers participated in this within-subjects study. Participants received LSD (75 µg, intravenously) on one occasion and placebo (saline, intravenously) on another, in a balanced order, with at least 2 weeks separating sessions. Acute subjective effects were measured using the Altered States of Consciousness questionnaire and the Psychotomimetic States Inventory (PSI). A measure of optimism (the Revised Life Orientation Test), the Revised NEO Personality Inventory, and the Peter's Delusions Inventory were issued at baseline and 2 weeks after each session.ResultsLSD produced robust psychological effects; including heightened mood but also high scores on the PSI, an index of psychosis-like symptoms. Increased optimism and trait openness were observed 2 weeks after LSD (and not placebo) and there were no changes in delusional thinking.ConclusionsThe present findings reinforce the view that psychedelics elicit psychosis-like symptoms acutely yet improve psychological wellbeing in the mid to long term. It is proposed that acute alterations in mood are secondary to a more fundamental modulation in the quality of cognition, and that increased cognitive flexibility subsequent to serotonin 2A receptor (5-HT2AR) stimulation promotes emotional lability during intoxication and leaves a residue of ‘loosened cognition’ in the mid to long term that is conducive to improved psychological wellbeing.
APA, Harvard, Vancouver, ISO, and other styles
7

Nichols, David E. "Dark Classics in Chemical Neuroscience: Lysergic Acid Diethylamide (LSD)." ACS Chemical Neuroscience 9, no. 10 (2018): 2331–43. http://dx.doi.org/10.1021/acschemneuro.8b00043.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Kawasaki, Aki. "Persistent Palinopsia Following Ingestion of Lysergic Acid Diethylamide (LSD)." Archives of Ophthalmology 114, no. 1 (1996): 47. http://dx.doi.org/10.1001/archopht.1996.01100130045007.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Sedwick, Lyn A. "Persistent Palinopsia Following Ingestion of Lysergic Acid Diethylamide (LSD)." Journal of Neuro-Ophthalmology 16, no. 3 (1996): 228. http://dx.doi.org/10.1097/00041327-199609000-00029.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Deruiter, Jack, F. Taylor Noggle, and C. Randall Clark. "Reversed Phase Liquid Chromatographic Separation of Lysergic Acid Diethylamide (LSD) and Lysergic Acid Methylpropylamide (LAMPA)." Journal of Liquid Chromatography 10, no. 15 (1987): 3481–88. http://dx.doi.org/10.1080/01483918708081885.

Full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "Lysergic acid diethylamide (LSD)"

1

Gomes, Melissa Medrano. "Dietilamida do ácido lisérgico (LSD) e N,N-dimetiltriptamina (DMT) como substratos de peroxidases: uma possível rota de metabolização." Universidade de São Paulo, 2008. http://www.teses.usp.br/teses/disponiveis/9/9136/tde-27032008-090215/.

Full text
Abstract:
Após um intervalo de duas décadas, ressurgiu um novo interesse em estudos sobre alucinógenos que visam a compreensão de como estes compostos interagem com o sistema nervoso central (SNC). Sabendo-se que enzimas do tipo peroxidases estão presentes em células do tipo leucócitos, neurônios e microglia, e que, são capazes de oxidar compostos indólicos, esta, portanto, poderia representar uma rota ativa de metabolização de alucinógenos no SNC, ainda não conhecida. Nesta perspectiva, este trabalho contribui com a descrição da metabolização da dietilamida do ácido lisérgico (LSD) e da N,N-dimetiltriptamina (DMT) por peroxidase de rábano (HRP) e mieloperoxidase (MPO) proveniente de neutrófilos ativados. A formação de produtos de reação foi acompanhada por HPLC com detectores de arranjo de diodos (DAD) e fluorescência, e a identificação por espectrometria de massas (MS). Ambas as peroxidases foram capazes de metabolizar LSD a compostos que coincidem com produtos de sua metabolização in vivo, como 2-oxo-3-hidroxi-LSD (O-H-LSD) e nor-LSD, por enzimas hepáticas do complexo P450. Entretanto, um terceiro produto formado não havia sido descrito anteriormente. Apresenta como característica principal a abertura do anel indólico e foi nomeado pelo nosso grupo como N,N-dietil-7-formamido-4-metil-6-oxo-2,3,4,4a,5,6-hexahidrobenzo[f]quinolina-2-carboxamida (FOMBK). De uma maneira semelhante, HRP e MPO também metabolizaram DMT a um produto hidroxilado (OH-DMT), que possivelmente apresenta considerável ação alucinógena, e a um segundo produto nomeado N,N-dimetil-N-formil-quinuramina (DMFK). Visto que peroxidases estão presentes em diferentes tipos celulares, é razoável supor que a formação dos produtos descritos neste estudo possa ocorrer in vivo, numa possível via alternativa de metabolização de LSD e DMT ainda não descrita em humanos.<br>After a gap of two decades a new interest in hallucinogen studies that aim the comprehension of how these compounds interact with the central nervous system (CNS) rose again. It is known that peroxidases enzymes are present in cells such as leukocytes, neurons and microglia and that they are capable of oxidizing indolic compounds. Then it could represent an active metabolization pathway for hallucinogens in the CNS, not known yet. In this perspective, this study contributed with the description of the metabolization of lysergic acid diethylamide (LSD) and N,N-dimethyltryptamine (DMT) by horseradish peroxidase (HRP) and myeloperoxidase (MPO) from activated neutrophils. The formation of the reaction products was attended by HPLC with diode array and fluorescence detectors, and the identification by mass spectrometry (MS). Both peroxidases were capable of metabolizing LSD to compounds that coincide with products from its in vivo metabolization, as 2-oxo-3-hydroxy-LSD (O-H-LSD) and nor-LSD by the liver enzymes from P450 complex. However, a third compound had not been described before. It has the opened indolic ring as main characteristic and was named by our group as N,N-diethyl-7-formamido-4-methyl-6-oxo-2,3,4,4a,5,6-hexahydrobenzo[f]quinoline-2-carboxamide (FOMBK). In a similar way, HRP and MPO also metabolized DMT to a hydroxylated product (OH-DMT) that possibly shows a considerable hallucinogen action and to a second product named as N,N-dimethyl-N-formyl-kynuramine (DMFK). Since peroxidases are present in different cell types, it is reasonable to assume that the formation of the products described in this study may occur in vivo as well, in a possible alternative metabolic pathway for LSD and DMT that has not been described in humans yet.
APA, Harvard, Vancouver, ISO, and other styles
2

Kerrigan, Sarah. "Immunochemical detection of lysergic acid diethylamide using a photochemically linked immunogen." Thesis, National Library of Canada = Bibliothèque nationale du Canada, 1997. http://www.collectionscanada.ca/obj/s4/f2/dsk3/ftp05/nq27177.pdf.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Larsson, Anisha Lela. "Mikrodosering av lysergsyradietylamid och psilocybin och dess effekter på psykisk hälsa." Thesis, Uppsala universitet, Institutionen för psykologi, 2018. http://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-358476.

Full text
Abstract:
Mikrodosering av psykedeliska droger är den senaste trenden som verkar ha fått en stor spridning, främst bland unga människor för att uppnå ökad produktivitet och kreativitet, men även för att uppnå allmän psykisk hälsa. Denna uppsats lägger fokus på lysergsyradietylamid (LSD) och psilocybin (magic mushroom). Mikrodosering innebär att användaren tar en väldigt låg dos av substansen. Dosen ger ingen psykedelisk effekt, d.v.s. inga visuella effekter, inget förändrat medvetandetillstånd,och ingen förändrad tids-eller rumsuppfattning. Deltagare (n=201) besvarade en elektronisk enkät som distribuerades i olika forum med intresse för psykedeliska substanser. I denna deskriptiva sambandsstudie undersöktes motiveringen av att mikrodosera LSD-och psilocybin, samt vilka positiva och negativa effekter mikrodosering av dessa substanser har på den psykiska hälsan.Deltagare uppgav upplevd minskad depression, ångest och stress, men att det inte var den primära anledningen till att de mikrodoserade trots att 62% hade självdiagnostiserat sig med någon form av upplevd ohälsa. De primära motiven med att mikrodosera, som angavs i enkäten, var att förbättra den allmänna hälsan, samt för att nå ökad kreativitet och produktivitet. Trots upplevda negativa bieffekter under mikrodoseringscykeln uppgav majoriteten att de ville fortsätta att mikrodosera. På grund av urvalet är studieresultatet inte generaliserbart och efterföljande undersökningar med hypoteser och frågor är att föreslå.
APA, Harvard, Vancouver, ISO, and other styles
4

Wihlbäck, Anna-Carin. "Ovarian hormones and effects in the brain : studies of neurosteroid sensitivity, serotonin transporter and serotonin2A receptor binding in reproductive and postmenopausal women." Doctoral thesis, Umeå universitet, Obstetrik och gynekologi, 2004. http://urn.kb.se/resolve?urn=urn:nbn:se:umu:diva-365.

Full text
Abstract:
Background: Estrogen has been reported to enhance well-being and quality of life during the climacteric phase. In women with an intact uterus estrogen treatment is always combined with progestins in order to protect the endometrium from hyperplasia and malignancies. However, in certain women the addition of progestins causes cyclicity in negative mood symptoms and physical symptoms similar to those encountered during ovulatory cycles in women with premenstrual dysphoric disorder (PMDD). The ovarian hormones estradiol and progesterone have profound effects on a number of neurotransmitter systems in the brain, such as the gamma aminobutyric acid (GABA) system and the serotonergic system. Progesterone metabolites, such as allopregnanolone and pregnanolone (also referred to as neurosteroids) modify the GABAA receptor in the central nervous system (CNS) and enhance GABAergic inhibitory transmission. Neurosteroid sensitivity in human studies can be studied by saccadic eye movement measurements using pharmacodynamic challenges with pregnanolone. Altered neurosteroid sensitivity has been suggested as a possible contributory factor to the progesterone/progestin-induced adverse mood effects of hormone replacement therapy (HRT). There is also evidence of estrogen treatment affecting the serotonergic system in postmenopausal women, although progestin addition has been less well studied. Aims and method: The aim was to investigate whether the negative mood symptoms experienced during the progestin or progesterone phase of HRT were associated with changes in neurosteroid sensitivity, or changes in platelet serotonin uptake site (transporter) and serotonin2A (5-HT2A) receptor binding. The intention was also to investigate whether hormonal changes during the normal menstrual cycle affect these peripheral serotonergic parameters. Postmenopausal women with climacteric symptoms were given HRT in two randomized, double-blinded, placebo-controlled crossover studies. The women received 2 mg estradiol (E2) continuously during 28- day cycles. Synthetic progestins or natural progesterone were added sequentially during the last 14 days, and compared to a placebo addition. Before treatment, as well as during the last week of each treatment cycle the pharmacodynamic response to pregnanolone was assessed using saccadic eye movement measurements. Throughout the studies daily symptom ratings were made. In the study regarding synthetic progestins, platelet serotonin transporter and 5-HT2A receptor binding were assayed before entering the study, as well as during the last week of each treatment cycle. In the study on reproductive women, blood samples were collected for analysis of platelet serotonin transporter and 5-HT2A receptor binding at six different points in time during the menstrual cycle. Results and conclusion: The addition of synthetic progestins to estrogen treatment increased negative mood symptoms and physical symptoms, whereas positive symptoms decreased. The addition of progestins also increased the sensitivity to pregnanolone. The addition of natural progesterone to estrogen treatment increased the sensitivity to pregnanolone. However, in this study the pregnanolone sensitivity was enhanced also during estrogen treatment. Women expressing cyclicity in negative mood symptoms were more sensitive to pregnanolone than women without symptom cyclicity. Thus, it is evident that mood deterioration during HRT is associated with altered neurosteroid sensitivity. Platelet serotonin transporter and 5-HT2A receptor binding did not change during the different treatment conditions in HRT. Thus, we were unable to explain the negative mood changes of HRT by use of these peripheral serotonergic parameters. In the study on reproductive women however, it was clear that the serotonergic variables did change during the menstrual cycle. Binding to the serotonin transporter was higher in the late follicular phase than in the ovulatory, early luteal or mid-luteal phases. Binding to the 5-HT2A receptor was higher in the early follicular phase and the early luteal phase than in the mid-luteal phase. These findings may provide a link between the ovarian steroids, and the GABAergic and serotonergic neurotransmitter systems, which in turn, could explain part of the specific vulnerability that women have for the development of adverse mood effects during HRT, mood and anxiety disorders and for the deterioration of mood so frequently seen during the luteal phase.
APA, Harvard, Vancouver, ISO, and other styles
5

Fang, Ching, and 方晴. "Determination of 3,4-Methylenedioxymethamphetamine and Lysergic Acid Diethylamide in Urine by Capillary Electrophoresis/Fluorescence Spectroscopy." Thesis, 2002. http://ndltd.ncl.edu.tw/handle/15640195684860786710.

Full text
Abstract:
碩士<br>國立臺灣師範大學<br>化學研究所<br>90<br>Abstract 3,4-methylenedioxyamphetamine (3,4-MDMA) is a strong central nervous system stimulant. Using nonaqueous capillary electrophoresis/fluorescence detection, the precision of the method was evaluated by measuring the repeatability and intermediate precision of migration time and corrected peak height by comparison with a 3,4-MDMA-D5 internal standard. It is possible to determine this drug at a level of 1 ppm without any pre-treatment in less than 5 min. After liquid-liquid extraction, the sample can be condensed and a detection limit of 3,4-MDMA in urine of 50 ppb (S/N = 3) can be achieved. Lysergic acid diethylamide (LSD) is a powerful psychedelic drug that produces temporary hallucinations and a schizophrenic psychotic state The separation and on-line concentrations of LSD, iso-lysergic acid diethylamide (iso-LSD) and lysergic acid N, N-methylpropylamide (LAMPA) in human urine also were investigated by capillary electrophoresis-fluorescence spectroscopy using a mixture of acetonitrile-methanol-water solution (5:35:60, v/v) containing sodium dodecyl sulfate (100 mM), phosphate (50 mM), and Brij-30 (3 mM). To improve sensitivity, a technique involving sweeping and cation-selective exhaustive injection-sweep-micellar electrokinetic chromato- graphy (CSEI-sweep-MEKC) were also used for on-line concentration which resulted in detection limits of ~ 20 ppb and ~ 60 ppt, respectively. The separation and on-line identification of LSD in tablets were also investigated by capillary electrophoresis-fluorescence spectroscopy at 77 K and GC/MS.
APA, Harvard, Vancouver, ISO, and other styles

Books on the topic "Lysergic acid diethylamide (LSD)"

1

SAM. The acid: On sustained experiment with lysergic acid diethylamide, or LSD. Vision, 2009.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
2

Grof, Stanislav. LSD: Doorway to the numinous : the groundbreaking psychedelic research into realms of the human unconscious. Park Street Press, 2009.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
3

Psychedelic psychiatry: LSD from clinic to campus. Johns Hopkins University Press, 2008.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
4

Psychedelic psychiatry: LSD on the Canadian prairies. University of Manitoba Press, 2012.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
5

The pharmacology of LSD: A critical review. Oxford University Press, 2010.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
6

Barber, Theodore X. LSD, marihuana, yoga, and hypnosis. Aldine/Transaction, 2007.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
7

Acid Christ: Ken Kesey, LSD and the politics of ecstasy. Schaffner Press, 2009.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
8

Hofmann, Albert. LSD, my problem child: And, Insights/outlooks. Beckley Foundation Press, 2013.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
9

Masters, Robert E. L. The varieties of psychedelic experience: The classic guide to the effects of LSD on the human psyche. Park Street Press, 2000.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
10

Stevens, Jay. Storming heaven: LSD and the American dream. Flamingo, 1993.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Book chapters on the topic "Lysergic acid diethylamide (LSD)"

1

Kryzhanovskaya, Ludmila A., and Catherine A. Leslie. "LSD (Lysergic Acid Diethylamide)." In Encyclopedia of the Neurological Sciences. Elsevier, 2003. http://dx.doi.org/10.1016/b0-12-226870-9/01163-1.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Holstege, Christopher P. "LSD (Lysergic Acid Diethylamide)." In Encyclopedia of Toxicology. Elsevier, 2005. http://dx.doi.org/10.1016/b0-12-369400-0/00570-6.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

"Lysergic Acid Diethylamide (LSD)." In Encyclopedia of Personality and Individual Differences. Springer International Publishing, 2020. http://dx.doi.org/10.1007/978-3-319-24612-3_301493.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

May, Paul, and Simon Cotton. "Lysergic Acid Diethylamide (LSD)." In Molecules That Amaze Us. CRC Press, 2014. http://dx.doi.org/10.1201/b17423-34.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

"Lysergic Acid Diethylamide (LSD)." In Medical Toxicology of Drug Abuse. John Wiley & Sons, Inc., 2012. http://dx.doi.org/10.1002/9781118105955.ch22.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

"Lysergic Acid Diethylamide (LSD)." In Hale’s Medications & Mothers’ Milk™ 2019. Springer Publishing Company, 2018. http://dx.doi.org/10.1891/9780826150356.0620.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Gewirtz, Eric. "Drug Abuse, Lysergic Acid Diethylamide (LSD)." In Essence of Anesthesia Practice. Elsevier, 2011. http://dx.doi.org/10.1016/b978-1-4377-1720-4.00119-9.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Halberstadt, Adam L., and Mark A. Geyer. "Neuropharmacology of Lysergic Acid Diethylamide (LSD) and Other Hallucinogens." In Biological Research on Addiction. Elsevier, 2013. http://dx.doi.org/10.1016/b978-0-12-398335-0.00061-3.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Rastegar, Darius A. "Hallucinogens and Dissociatives." In ASAM Handbook of Addiction Medicine. Oxford University Press, 2020. http://dx.doi.org/10.1093/med/9780197506172.003.0009.

Full text
Abstract:
Hallucinogens, also referred to as psychedelics, are a broad range of agents that alter perception in different ways. An estimated 1.3 million Americans are current (past month) users of hallucinogens. Hallucinogen use is highest among young adults; 3,4-methylenedioxymethamphetamine (MDMA) is the most commonly used agent, followed by lysergic acid diethylamide (LSD) and phencyclidine (PCP). Hallucinogens alter sensory perception and change the qualities of thought or emotion. PCP, MDMA, and LSD can be detected in urine drug tests. There appear to be few serious lasting complications associated with hallucinogen use. There are few data on the treatment of individuals who use hallucinogens or dissociatives.
APA, Harvard, Vancouver, ISO, and other styles
10

Winstock, Adam R., and James Rucker. "Psychedelics and dissociative substances." In New Oxford Textbook of Psychiatry, edited by John R. Geddes, Nancy C. Andreasen, and Guy M. Goodwin. Oxford University Press, 2020. http://dx.doi.org/10.1093/med/9780198713005.003.0054.

Full text
Abstract:
Psychedelics and hallucinogens represent some of the most commonly used drugs in the world, with a history of use steeped in spirituality, counter-culture, and more recently latent therapeutic potential. Sharing a common mechanism of action at the 5-HT2a receptor, drugs such as lysergic acid diethylamide (LSD) and psilocybin, while they can rarely induce significant short-term psychopathology, are remarkably safe physiologically, do not cause dependence, and are now being actively researched again for their therapeutic potential in non-psychotic conditions such as anxiety, addictions, and depression. Ketamine is also being explored as a treatment for resistant depression and is in common use as an anaesthetic. However, it has increasingly become recognized as a drug with abuse potential. Although safe in overdose, ketamine carries acute risks related to vulnerability while intoxicated, and chronic use is associated with urinary tract toxicity.
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'Lysergic acid diethylamide (LSD)' for particular source types:
Journal articles Books
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography